Hepatic Impaired Subjects Compared to Healthy Subjects Receiving Multi-dose BMS-650032

Summary

The purpose of this study is to assess the effects of hepatic impairment on the multiple dose pharmacokinetics of BMS-650032.

Timeline

Start

2009-12

Primary completion

2011-08

Completion

2011-08

Publications

• Eley T, He B, Chang I, Colston E, Child M, Bedford W, Kandoussi H, Pasquinelli C, Marbury TC, Bertz RJ. The effect of hepatic impairment on the pharmacokinetics of asunaprevir, an HCV NS3 protease inhibitor. Antivir Ther. 2015;20(1):29-37. doi: 10.3851/IMP2773. Epub 2014 Apr 7.

Drugs

Indications